Introduction {#S1}
============

Influenza A virus H3N2 first emerged in 1968, and frequently leads to annual outbreaks within the human population ([@B22]). Important contributions to the pandemic of influenza have come from hemagglutinin (HA), which is a major surface antigen of the virus. Mutations in the HA may cause affecting receptor binding and immune response. Thus, understanding the novel mutation is critical for developing strategies to control the pandemic of influenza A (H3N2).

The hemagglutinin (HA) protein plays an important role in binding host cell receptors and releasing the viral RNA into the cell ([@B5]). HA is composed of two polypeptides, HA1 and HA2. HA1 contains the receptor binding site in a globular head domain and targets sialic acid residues on host cells. HA2 forms a stem-like structure containing a fusion domain (N-terminal) and a transmembrane anchor domain (C-terminal), and mediates fusion of the virus envelope and endosomal membrane ([@B29]). Both regions contain N-linked oligosaccharides ([@B17]), which may interfere with the function of HA. The majority of oligosaccharides are conserved and promote fusion activity. But glycans near the antigenic epitopes may influence the antibody recognition and those near the proteolytic activation site may affect the infectivity of the influenza virus ([@B28]; [@B11]).

HA mutations of influenza A (H3N2) have been emerging with changes of glycosylation since 1968. Influenza A (H3N2) has re-assorted with an H2N2 virus, the former virus is capable of transmission between humans ([@B34]; [@B25]). The H3N2 virus mutated so quickly that the World Health Organization (WHO) has recommended 28 vaccine strains ([@B19]). The rapid mutation rate of the H3N2 virus has been proposed to lead to generation of a novel virus in 2--5 years ([@B23]). In the 2014/15 season, two new clades started to emerge. Clade 3c.2a, characterized by the F159Y and K160T mutations, bore a novel potential glycosylation site ([@B7]; [@B30]). Another clade in circulation was 3c.3a (including strain A/Switzerland/9715293/2013) ([@B7]). During the 2016/17 season, clade 3c.2a separated into two new clades. The 3c.2a1, characterized by amino acid changes such as T135K, N171K, and D122N, may have resulted in the loss of a glycosylation site ([@B21]). By the 2017/18 season, clade 3c.2a2 began to split into cluster I, bearing the I58V and S219K mutations, and cluster II, bearing the N122D and S262N mutations. The N122D mutation resulted in the loss of a glycosylation site ([@B14]). Generally, the HA1 genes of H3N2 viruses undergo continuous mutations result in losing or possessing of glycosylation to reduce host immune recognition and to enhance transmissibility ([@B15]; [@B24]). The majority of neutralizing antibodies induced by vaccination or infection do not target the receptor-binding site (RBS), which is surrounded by highly variable regions of HA1, and prevent virus binding to cell receptors ([@B12]; [@B18]; [@B35]).

Besides, the HA protein is critical for the virulence and host preference as it binds to sialic acid receptors on epithelial cells ([@B27]; [@B10]). It was reported that mutation of HA glycosylation sites can affect the specificity and affinity for receptor binding ([@B20]). As the amount of glycans becomes more, the binding ability for the receptor is weakened ([@B1]). However, influenza will undergo multiple mutations to make a successful adaptation to humans.

Overall, the number and position of *N*-linked glycans in HA have influenced the evolution of H3N2 viruses and can contribute to immune evasion ([@B33]; [@B31]). In our study, we identified H3N2 clinical strains from Guangdong, China, in 2017 that were not able to bind RBCs. The surface of RBCs contains many receptors for binding by HA. RBCs clump together because of interactions between the HA of virus particles and RBCs, leading to a lattice formation, which called the hemagglutination assay ([@B13]). This suggested that H3N2 virus epitopes may change and influence binding to host cell receptors as well as antibody responses. Therefore, it is necessary to provide further insights into the genetic characteristics and glycosylation changes of H3N2 viruses.

Materials and Methods {#S2}
=====================

Cells and Viruses {#S2.SS1}
-----------------

Madin-Darby canine kidney (MDCK) cells were purchased from the American Tissue Culture Collection (ATCC). The cells were cultured in minimum Eagle's medium containing 10% heat-inactivated fetal bovine serum. Influenza A viruses A/Brisbane/10/2007 (H3N2) (B10) and A/Hong Kong/4801/2014 (H3N2) (HK4801) were also purchased from the ATCC. Influenza A viruses A/China/LZP/2017 (H3N2) LZP) and A/China/GMU-SKLRD03/2017 (H3N2) (GMU03) were detected and isolated from clinical specimens. Collection of clinical specimens was approved by the Ethics Committee of The First Affiliated Hospital of Guangzhou Medical University (2014 No. 50; Guangzhou, China; File number: 2014-50, date: June 2, 2015). Written informed consent was obtained from study participants.

Viral Genome Characterization and Reverse Genetics {#S2.SS2}
--------------------------------------------------

RNA of the four H3N2 strains was extracted and reverse transcribed. The sequences of LZP and GMU03 were deposited in GenBank (LZP: Accession numbers [MK053902](MK053902) to [MK053909](MK053909); [GMU03](GMU03): Accession numbers [MN658587](MN658587)). The eight viral segments of different strains were amplified and cloned into a pHW2000 plasmid system as previously described ([@B32]). The seven segments of LZP (NA, PB1, PB2, PA, NP, M, NS) were used as a backbone to rescue recombinant viruses (LZP-B10, LZP-HK4801, LZP-GMU03) bearing the HA genes of B10, HK4801, and GMU03, respectively.

Hemagglutination Assay {#S2.SS3}
----------------------

The hemagglutination assay was performed in a V-bottom 96-well microtiter plate. The most concentrated sample was in the first well, and subsequent wells were serially diluted twofold in phosphate-buffered saline (PBS). The first row served as a negative control and contained only PBS. Different strains of virus were detected by 0.5% solution of turkey RBCs.

Quantitative Real-Time PCR (qPCR) {#S2.SS4}
---------------------------------

RNA from wild type and recombinant H3N2 viruses was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Germany) and analyzed by qPCR using the ABI 7500 Real-time PCR System ([@B32]).

Direct Immunofluorescence Assay (DFA) {#S2.SS5}
-------------------------------------

The nucleoproteins (NPs) of H3N2 viruses were detected using the D3 Ultra DFA Respiratory Virus Screen and ID Kit (Healthline Media UK Ltd., Brighton, United Kingdom). H3N2 strains (LZP, GMU03) and B10- or HK4801-infected cells were fixed in 4% paraformaldehyde at 37°C for 30 min. Fluorescein isothiocyanate (FITC)-labeled mouse anti-NP antibody was used to detect nucleoprotein. The cells were observed using a fluorescence microscope (Zeiss Axiovert 135, Zeiss, Oberkochen, Germany).

Bioinformatic Analysis {#S2.SS6}
----------------------

The HA genes of B10 and HK4801 were obtained from the National Center for Biotechnology Information (NCBI) Influenza Virus Resource Database and the HA genes of LZP and GMU03 were sequenced by Sangon Biotech (Shanghai, China). Both sequences were analyzed using Vector NTI (Invitrogen, United States). The prevalence of the T160K, N158K and the substitutions at residues 158--160 were analyzed through the Global Initiative on Sharing All Influenza Data (GISAID) database^[1](#footnote1){ref-type="fn"}^.

Mutation of H3N2 HA1 N158K and T160K {#S2.SS7}
------------------------------------

Mutations were introduced at HA1 residues 158 and 160 using the QuikChange site-directed mutagenesis kit (Agilent Technologies, Santa Clara, United States). HA1-N158K and HA1-T160K mutant viruses were rescued as described previously ([@B16]).

Enzymatic Digestion of Influenza Proteins {#S2.SS8}
-----------------------------------------

Influenza proteins were purified by filtration through a 10-kDa cutoff centrifugal filter, and sequentially treated with 10 mM dithiothreitol and 2 M hydroxylamine. The samples were alkylated with 55 mM iodoacetamide. Next, the samples were concentrated and buffer-exchanged buffer into H~2~O using a 3-kDa cutoff centrifugal filter. The protein concentration was determined using a Bio-Rad protein assay.

Fifty micrograms of protein were diluted with 100 mM Tris-HCl containing 10 mM CaCl~2~ (pH 8.0) to a final concentration of 1 μg/μL. Two micrograms of chymotrypsin were added and incubated for 16 h incubation at 25°C. The digested samples were loaded onto the preconditioned porous graphitic carbon cartridge and targeted glycopeptides were eluted with 50% acetonitrile (ACN) containing 0.1% trifluoroacetic acid. The collected fraction was dried using a speed vacuum. Finally, the dried residue was reconstituted in 50 μL of MilliQ H~2~O prior to analysis.

Glycopeptide Profiling by C18 Chip-Q-TOF-MS {#S2.SS9}
-------------------------------------------

Chromatographic separation of glycopeptides was performed on an Agilent 1260 Infinity HPLC Chip LC system (Agilent, Santa Clara, CA, United States) equipped with a Polaris-HR C18 chip (G4240-62030, Agilent). Three microliters of each sample were loaded onto the enrichment column in a solution of 0.1% formic acid (FA) and 3% ACN in water at 3 μL/min. The mobile phase used in the nano-pump consisted of 0.1% FA in water (A) and 0.1% FA in ACN (B). The gradient was as follows: 3--40% B for 15 min, 40--70% B for 1 min, 70% B for 1 min, 70--3% B for 0.5 min, and 3% B for 10 min. The flow rate was 0.45 μL/min.

Glycopeptide profiling was carried out on an Agilent 6550 iFunnel Q-TOF MS. The dry gas (N~2~) was flowed at 11 L/min at 250°C. MS spectra were acquired in positive mode with the mass range m/z 450--3000. Mass correction was enabled using reference masses of m/z 922.0098.

Ethics Approval and Consent to Participate {#S2.SS10}
------------------------------------------

All clinical specimens have been approved from the Ethics Committee of The First Affiliated Hospital of Guangzhou Medical University (2014 no. 50; Guangzhou, China) (File number: 2014-50 date: June 2, 2015). Written informed consent was obtained from the participant.

Results {#S3}
=======

Detection of H3N2 Clinical Specimens {#S3.SS1}
------------------------------------

LZP and GMU03 were negative by hemagglutination assay. The positive controls, B10 and HK4801 were positive and their hemagglutination titers were 1:64 and 1:512, respectively ([Table 1](#T1){ref-type="table"} and [Supplementary Figure S1](#FS1){ref-type="supplementary-material"}). To determine whether the two clinical isolates were truly negative for hemagglutination activity, we used qPCR and DFA. The CT values of LZP and GMU03 were 21.85 and 23.14, respectively, by qPCR ([Table 1](#T1){ref-type="table"}). The viral NPs of the H3N2 viruses were detected by DFA using a FITC-labeled mouse anti-NP antibody ([Figure 1](#F1){ref-type="fig"}).

###### 

qPCR for detecting HA in H3N2 clinical specimens.

  Species of virus                  Hemagglutination assay   qPCR (CT values)
  --------------------------------- ------------------------ ------------------
  A/China/LZP/2017 (H3N2)           (--)                     21.85
  A/China/GMU-SKLRD03/2017 (H3N2)   (--)                     23.14
  A/Brisbane/10/2007                (+) 1:64                 15.08
  A/Hong Kong/4801/2014 (H3N2)      (+) 1:512                14.24

(+), positive; (--), negative. Throat swabs (LZP, GMU03) were collected from patients with acute respiratory tract infection (ARTI) in Guangdong, China during 2017. The viral RNA/DNA was extracted and reverse transcribed. The HA of A (H3N2) was determined by qPCR kit. Meanwhile, the clinical specimens were tested using the HA assay.

![Immunofluorescence assay for detecting H3N2 clinical specimens. The nucleoproteins (NPs) of H3N2 viruses were determined by the D3 Ultra DFA Respiratory Virus Screen and ID Kit. H3N2 strains (LZP, GMU03) and B10- or HK4801-infected cells were fixed in 4% paraformaldehyde at 37°C for 30 min. FITC-labeled mouse anti-NP antibody was used to detect nucleoprotein. The cells were observed using a fluorescence microscope.](fmicb-11-01318-g001){#F1}

Determination of Critical Viral Proteins {#S3.SS2}
----------------------------------------

To confirm whether the HA protein affected the binding ability of viruses to RBCs, LZP-03, LZP-B10, and LZP-4801 H3N2 viruses were rescued as recombinant viruses. LZP and LZP-GMU03 recombinant viruses were both negative by hemagglutination assay ([Figure 2](#F2){ref-type="fig"}). However, the LZP-B10 and LZP-HK4801 recombinant viruses showed hemagglutination activity at titers of 1:64 and 1:16, respectively. Thus, negative results in hemagglutination assays were caused by the HA proteins of H3N2 viruses.

![Hemagglutination titers of H3N2 recombinant viruses. To figure out whether HA protein of LZP led to unable to bind the RBCs, the seven segments of LZP (NA, PB1, PB2, PA, NP, M, NS) were used as a backbone to rescue recombinant viruses (LZP-B10, LZP-HK4801, LZP-GMU03) bearing the HA genes of B10, HK4801, and GMU03, respectively. The recombinant viruses and LZP were determined by HA assay. A: PBS; B: LZP; C: LZP-GMU03; D: LZP-B10; E: LZP-HK4801.](fmicb-11-01318-g002){#F2}

Identification of Mutated Sites in A/China/LZP/2017 (H3N2) {#S3.SS3}
----------------------------------------------------------

To identify important mutations, the HA sequences of LZP and GMU03 were compared with those of B10 and HK4801. Two mutations in the HA protein were found: HA1-K121N and HA1-T160K.

Critical Nature of the N158K and T160K Mutations in A/China/LZP/2017 (H3N2) {#S3.SS4}
---------------------------------------------------------------------------

According to the GISAID database, a Thr substitution at HA1 residue 160 H3N2 viruses rose in frequency from 2013 to the present day. By contrast, the peak frequency of K160 occurred in 2012 (2848/2850 isolates, 99.93%) and then gradually declined ([Figure 3](#F3){ref-type="fig"}). After incorporating a T160K mutation in LZP, the hemagglutination assay was positive with a titer of 1:64. However, the frequency of K160 started to rise in 2018. In addition, another critical substitution of LZP was identified at HA1 residue 158. When Asn was substituted with Lys at this position, a positive result was also obtained in the hemagglutination assay ([Figure 4](#F4){ref-type="fig"}). Both N158K and T160K of LZP could change the binding ability to RBCs. From 2013 to present, the frequency of the N-X-T motif at residues 158--160 increased worldwide and became dominant in 2015 (5198/6805 isolates, 76.4%), where X is any amino acid except Pro. In Guangdong, China, the N-X-T motif began to dominate in 2016 (6/8 isolates, 75%) ([Figures 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}).

![Prevalence of T and K residues at HA1 position 160 in the world since 1968. The sequences of 62330 clinical strains worldwide from 1968 to 2019 were collected from GISAID. The T and K residues at HA1 position 160 were analyzed. The y-axis on the left: the number of HA1-160T and HA1-160K; The y-axis on the right: the percentage of HA1-160T and HA1-160K.](fmicb-11-01318-g003){#F3}

![Hemagglutination titers of H3N2 mutant strains. To distinguish whether the possessing of glycosylation motif site at position 158 failed to bind RBCs, recombinant virus containing HA1-160K, HA1-158K, and LZP were determined by HA assay. A: PBS; B: LZP; C: T160K; D: N158K.](fmicb-11-01318-g004){#F4}

![Worldwide prevalence of the glycosylation motif site at position 158 from 1968 to 2019. The sequences of 62,330 clinical strains worldwide from 1968 to 2019 were collected from GISAID. The substitutes at position 158--160 were analyzed.](fmicb-11-01318-g005){#F5}

![Prevalence of the N-X-T/K motif in Guangdong, China from 2012 to 2019. The sequences of 106 clinical strains in Guangdong, China from 2012 to 2019 were collected from GISAID. The substitutes N-X-T/K at position 158--160 were analyzed. The y-axis on the left: the number of the substitutes N-X-T and N-X-K at HA1 residues 158--160; The y-axis on the right: the percentage of the substitutes N-X-T and N-X-K at HA1 residues 158--160.](fmicb-11-01318-g006){#F6}

Glycopeptide Profiling of HA1 Residue 158 {#S3.SS5}
-----------------------------------------

N-linked glycans can only be attached to the nitrogen atom of an N residue that forms part of the consensus sequence N-X-Ser(S)/T. Therefore, one chymotryptic glycopeptide at residues 154--159 (peptide sequence: LTHLNY) of HA, which possessed a glycosylation site at HA1 residue 158, was identified in LZP. Based on the high-resolution MS data and matching with the database, 10 glycoforms were identified at residue HA1 position 158 including three neutral glycans (3_6\_2_0, 4_3\_1_0, and 4_4\_3_0), three acidic glycans (5_6\_0_1, 3_3\_0_1, and 3_7\_0_2), and four sulfated glycans \[6_7\_0_0 (SO~3~), 4_3\_1_2 (SO~3~), 7_5\_2_0 (SO~3~), and 3_6\_2_1 (SO~3~)\] ([Figure 7](#F7){ref-type="fig"}). Both the N158K and T160K mutations resulted in loss of this glycosylation site.

![Overlaid extracted compound chromatograms (ECCs) of identified HA1 glycopeptides containing the glycosylation site at position 158. HA1 proteins extracted from influenza were digested with chymotrypsin at 25°C for 16 h, followed by profiling the glycopeptides by C18 chip-Q-TOF-MS. The glycoforms at position 158 were then identified based on high-resolution MS data. **(A)**: 4_3\_1_0, **(B)**: 3_6\_2_0, **(C)**: 5_6\_0_1, **(D)**: 4_3\_1_2 (SO3), **(E)**: 3_3\_0_1, **(F)**: 7_5\_2_0 (SO3), **(G)**: 4_4\_3_0, **(H)**: 3_6\_2_1 (SO3), **(I)**: 6_7\_0_0 (SO3), **(J)**: 3_7\_0_2.](fmicb-11-01318-g007){#F7}

Discussion {#S4}
==========

Influenza is a global threat and represents a pressing public health challenge worldwide ([@B26]). In China, an outbreak of influenza A H3N2 occurred during 2017 ([Supplementary Figure S2](#FS1){ref-type="supplementary-material"}). We found that some H3N2 strains in Guangdong did not bind RBCs and tested negative by hemagglutination assay. To confirm this result, we collected several clinical H3N2 strains, along with B10 and HK4801 as positive controls, and analyzed their genetic characteristics. As HA protein is present on enveloped viruses such as influenza viruses, it is able to bind receptors on the membranes of RBCs to cause agglutination ([@B13]). By inserting the HA genes of GMU03, B10, HK4801 into an LZP backbone, we were able to use a hemagglutination assay to deeply analyze the HA proteins of LZP and GMU03. We found that HA1 121K and 160T may play an important role in binding to RBCs. According to the GISAID database, the frequency of HA1 K160 has risen since 2017 worldwide, but T160 was still dominant in these years. Another residue, HA1 158, was also investigated. We mutated N158K and T160K and found that both strains were positive by HA assay, which suggested that mutations at both residues were responsible for failure to bind RBCs. In Guangdong Province, more isolates bore N-X-T substitutions at HA1 residues 158--160 during 2017. Further, we found that HA1 residue 158 of LZP bore an *N*-linked glycosylation site by enzymatic digestion of influenza proteins and C18 Chip-Q-TOF-MS analysis. In summary, our study confirmed that glycosylation at HA1 residues 158--160 can block receptor binding to RBCs.

It was reported that the loss and possessing of the glycosylation sites in the head region could affect recognition by antibodies. During the 2016/2017 season, [@B21] demonstrated that the T135K, N171K, and D122N substitutions were located within antigenic sites and potentially affected viral antigenicity, as they resulted in losses of *N*-linked glycosylation sites. Furthermore, the I58V and S219K mutations of clade 3c.2a2, cluster I and the N122D and S262N mutations of cluster II were found to result in the loss of a glycosylation site during the 2017/18 season ([@B14]). Nevertheless, since transmitting between the human population, HK/68 have gained up to seven glycosylation sites on the HA globular head and five on the stem from the only original two sites ([@B36]; [@B3]). In our study, we found that strains encoding 160T and 158N began to dominate in Guangdong Province, China during the 2015/16 season, leading to a new potential glycosylation site. Similar to previous studies, they concluded that the glycosylation site was a crucial factor affecting the antibody response. [@B9] demonstrated that residues 158--160 in the H3N2 hemagglutinin globular head had structural significance for antigenic drift by modeling. Moreover, [@B5] screened the epitopes of anti-A/Victoria/361/2011 neutralizing mouse monoclonal antibodies (mAbs) and found that HA1 residue 158 was glycosylated leading to reduce binding by mAbs. [@B37] also found that the generation of protective antibody responses against a H3N2 vaccine strain was affected during the 2016--2017 H3N2 influenza season due to the substitutions within HA1 residue 160 resulting in a new glycosylation site in the HA protein, which affected antigenicity. Generally, the addition or deletion of glycosylation sites on the globular head is vital for escaping the immune response of human. We supposed that the possessing of the glycan at HA1 residue 158 may be a important contribution for antigenic drift in Guangdong, China in recent years.

Not only the glycosylation site, the length and the type of the glycans on the HA head region may be other reasons underlying our observations. In our study, we discovered 10 different glycoforms at residue 158 \[4_3\_1_0, 5_6\_0_1, 3_3\_0_1, 4_4\_3_0, 6_7\_0_0 (SO~3~), 3_6\_2_0, 4_3\_1_2 (SO~3~), 7_5\_2_0 (SO~3~), 3_6\_2_1 (SO~3~), and 3_7\_0_2\]. As the length of the glycans, [@B8] reported that antibodies raised against the fully glycosylated HA were less binding affinity to antibody than bearing a single N-linked GlcNAc at each glycosylation site and implicated that removal of structural and non-essential glycans on viral glycoproteins might be an effective approach for vaccine design. Melissa Boeijen reviewed that long oligosaccharide side chains can block the binding of neutralizing antibody due to coverage of the antibody binding site and mentioned that galactose and fucose were long glycans ([@B6]). In the study, the length of glyforms were ranked as followed: 7_5\_2_0 (SO~3~) \> 4_3\_1_2 (SO~3~), 5_6\_0_1 \> 4_3\_1_0, 4_4\_3_0, 6_7\_0_0 (SO~3~) \> 3_3\_0_1, 3_6\_2_1 (SO~3~), 3_7\_0_2 \> 3_6\_2_0. Therefore, we suggested that 7_5\_2_0 (SO~3~) should be highly concerned. Additionally, the type of oligosaccharides side chains is critical as well to result in antigenic drift. A recent study by [@B4] supposed that the globular head region with high-mannose and complex glycans would promote the virus well shielding under the immune system. As we found, 3_6\_2_0, 5_6\_0_1, 7_5\_2_0 (SO~3~), 3_6\_2_1 (SO~3~), 6_7\_0_0 (SO~3~), 3_7\_0_2 are large, complex glycans on the N158 glycosite. Thus, not only the length but also the types of glycoform are crucial factors to affect immune responses, disturbing antibody recognition by steric hindrance of the binding site.

Since the N-X-T motif at residue 158--160 started to increase in prevalence worldwide in 2015, the WHO still recommended the vaccine strain (A/Hong Kong/4801/2014) until September 2017 ([@B2]). In Guangdong, China, the N-X-T motif became dominant in 2016. Before September 2017, the potential glycosylation site at residue 158 resulted in disruption of antibody recognition. Despite the WHO updating the vaccine strain to A/Singapore/INFIMH-16-0019/2016 bearing a glycosylation site at residue 158, an H3N2 outbreak still occurred in Guangdong, China in 2019. This may affect the vaccine strategy of local government or represent new drift mutations in H3N2 viruses. However, the N-X-T motif at residues 158--160 and the resulting potential glycosylation site will be a focus in Guangdong, China in the future.

A limitation of our study was that we lacked a large number of clinical specimens to be analyzed. In addition, we will continue to test protective antibody responses against the circulating H3N2 virus by generating mAbs and human serum.

Conclusion {#S5}
==========

Glycosylation at HA1 residues 158--160 of circulating H3N2 viruses in Guangdong, China in 2017 blocked binding to RBC receptors. Introduction of glycosylation sites and glycoform variation can affect protective antibody responses, and thus are critical for guiding vaccine strain selection in specific areas.
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